Drug Pipeline

Neratinib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
12
Active Studies
9
Recruiting
1
Phase 3
10
Top Sponsors
Active Studies by Phase
Phase 3
1
Phase 2
7
Phase 1/2
2
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05615818 Personalized Medicine for Advanced Biliary Cancer Patients Biliary Tract Neoplasms Recruiting
Phase 2
NCT05933395 Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor Advanced Breast Cancer Recruiting
NCT06109467 Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2… GastroEsophageal Cancer Recruiting
NCT04886531 Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive… Breast Cancer Recruiting
NCT01042379 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Breast Neoplasms Recruiting
NCT04374305 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related… Neurofibromatosis Type 2 Recruiting
NCT05564377 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced… Advanced Malignant Solid Neoplasm Recruiting
NCT06126276 Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted… Malignant Female Reproductive System Neoplasm Recruiting
Phase 1/2
NCT03919292 Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Solid Tumor, Adult Recruiting
NCT03377387 Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast… Breast Cancer Active, Not Recruiting
Phase 1
NCT03065387 Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With… Advanced Malignant Solid Neoplasm Active, Not Recruiting
NCT04502602 Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced… Advanced Solid Tumor Active, Not Recruiting
Sponsors Running Neratinib Trials
Disease Areas
Get alerts when Neratinib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free